Binimetinib (Mektovi®)


Indications for Prior Authorization:
  • Indicated in combination with Braftovi™ (encorafenib capsules), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA approved test.
The following criteria must be met:
  • Medication is prescribed by or in consultation with an oncologist, AND
  • Patient has unresectable, advanced, or metastatic melanoma, AND
  • Patient has melanoma with BRAF V600 mutation, AND
  • Mektovi will be used in combination with Braftovi™ (encorafenib capsules)
  • 45 mg orally taken twice daily in combination with encorafenib until disease progression or unacceptable toxicity.

1 year

Last review date: August 27, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.